Abstract:Bronchopulmonary dysplasia (BPD) is one of the few diseases affecting premature infants that have continued to evolve since its first description about half a century ago. The current form of BPD, a more benign and protracted respiratory failure in extremely preterm infants, is in contrast to the original presentation of severe respiratory failure with high mortality in larger premature infants. This new BPD is end result of complex interplay of various antenatal and postnatal factors causing lung injury and subsequent abnormal repair leading to altered alveolar and vascular development. The change in clinical and pathologic picture of BPD over time has resulted in new challenges in developing strategies for its prevention and management. While some of these strategies like Vitamin A supplementation, caffeine and volume targeted ventilation have stood the test of time, others like postnatal steroids are being reexamined with great interest in last few years. It is quite clear that BPD is unlikely to be eliminated unless some miraculous strategy cures prematurity. The future of BPD prevention will probably be a combination of antenatal and postnatal strategies acting on multiple pathways to minimize lung injury and abnormal repair as well as promote normal alveolar and vascular development.
Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia[J]. N Engl J Med, 1967, 276 (7): 357-368.
[2]
Jain D, Bancalari E. Bronchopulmonary dysplasia: clinicalperspective[J]. Birth Defects Res A Clin Mol Teratol, 2014, 100 (3): 134-144.
[3]
Norman JE, Marlow N, Norrie J, et al. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double blind trial[J]. Lancet, 2016, 387 (10033): 2106-2116.
[4]
Howson CP, Kinney M, Lawn JE. March of Dimes, PMNCH, Save the Children, WHO. Born Too Soon: The Global Action Report on Preterm Birth[R]. Geneva: World Health Organization, 2012.
[5]
Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth[J]. Cochrane Database Syst Rev, 2006, (3): CD004454.
[6]
Watterberg KL, Demers LM, Murphy S, et al. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops[J]. Pediatrics,1996, 97 (2): 210-215.
[7]
Prendergast M, May C, Greenough A, et al. Chorioamnionitis, lung function and bronchopulmonary dysplasia in prematurely born infants[J]. Arc Dis Child Fetal Neonatal Ed, 2011, 96 (4): F270-F274.
[8]
Hillman NH, Moss TJ, Kallapur SG, et al. Brief, large tidal volume ventilation initiates lung injury and a systemic response in fetal sheep[J]. Am J Respir Crit Care Med, 2007, 176 (6): 575-581.
[9]
Schmolzer GM, Kumar M, Cheung PY, et al. Sustained inflation versus positive pressure ventilation at birth: a systematic review and meta-analysis[J]. Arch Dis Child Fetal Neonatal Ed, 2015, 100: F361-F368.
Oei JL, Vento M, Saugstad OD, et al. Higher or lower oxygen for delivery room resuscitation of preterm infants below 28 completed weeks gestation: a meta-analysis[J]. Arch Dis Child Fetal Neonatal Ed, 2017, 102: F24-F30.
[12]
Rabi Y, Lodha A, Soraisham A, et al. Outcomes of preterm infants following the introduction of room air resuscitation[J]. Resuscitation, 2015, 96: 252-259.
[13]
Oei JL, Saugstad OD, Tarnow-Mordi W, et al. Targeted oxygen in the resuscitation of preterm infants, a randomized clinical trial[J]. Pediatrics, 2017, 139 (1): e20161452.
[14]
Soll RF. Synthetic surfactant for respiratory distress syndrome in preterm infants[J]. Cochrane Database Syst Rev, 2000, (2): CD001149.
[15]
Isayama T, Iwami H, Beyene J, et al. Association of noninvasive ventilation strategies with mortality and bronchopulmonary dysplasia among preterm infants. A systematic review and meta-analysis[J]. JAMA, 2016, 316 (6): 611-624.
[16]
Hascoet JM, Picaud JC, Vieux R, et al. Late surfactant administration in very preterm neonates with prolonged respiratory distress and pulmonary outcomes at 1 year of age: A randomized clinical trial[J]. JAMA Pediatr, 2016, 170 (4): 365-372.
[17]
Ballard RA, Keller RL, Palermo L, et al; TOLSURF Study Group. Randomized trial of late surfactant treatment in ventilated preterm infants receiving inhaled nitric oxide[J]. J Pediatr, 2016, 168: 23-29.
[18]
Avery ME, Tooley WH, Hansen TN, et al. Is chronic lung disease in low birth infants preventable? A survey of eight centers[J]. Pediatrics, 1987, 79 (1): 26-30.
[19]
Finer NN, Carlo WA, Higgins RD, et al; SUPPORT Study group. Early CPAP versus surfactant in extremely preterm infants[J]. N Engl J Med, 2010, 362 (21): 1970-1979.
[20]
Fischer HS, Buhrer C. Avoiding endotracheal ventilation to prevent bronchopulmonary dysplasia: a meta-analysis[J]. Pediatrics, 2013, 132 (5): e1351-e1360.
[21]
Kugelman A, Feferkorn I, Bader D, et al. Nasal intermittent mandatory ventilation versus nasal continuous positive airway pressure for respiratory distress syndrome: a randomized, controlled, prospective study[J]. J Pediatr, 2007, 150 (5): 521-526.
[22]
Oncel MY, Arayici S, Dilmen U, et al. Nasal continuous positive airway pressure versus nasal intermittent positive pressure ventilation within the minimally invasive surfactant therapy approach in preterm infants: a randomised controlled trial[J]. Arch Dis Child Fetal Neonatal Ed, 2016, 101 (4): F323-F328.
[23]
Kirpalani H, Millar D, Roberts RS, et al; NIPPV Study Group. A trial comparing noninvasive ventilation strategies in preterm infants[J]. N Engl J Med, 2013, 369 (7): 611-620.
[24]
Lemyre B, Davis PG, Kirpalani H, et al. Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for preterm infants after extubation[J]. Cochrane Database Syst Rev, 2014, (9): CD003212.
[25]
Yoder BA, Stoddard RA, Abbasi S, et al. Heated, humidified high-flow nasal cannula versus nasal CPAP for respiratory support in neonates[J]. Pediatrics, 2013, 131 (5): e1482-e1490.
[26]
Wilkinson D, Andersen C, Manley BJ, et al. High flow nasal cannula for respiratory support in preterm infants[J]. Cochrane Database Syst Rev, 2016, (2): CD006405.
[27]
Roberts CT, Owen LS, Davis PG, et al. HIPSTER Trial Investigators. Nasal high-flow therapy for primary respiratory support in preterm infants[J]. N Eng J Med, 2016, 375 (12): 1142-1151.
[28]
Thome UH, Genzel-Boroviczeny O, Hummler HD, et al. PHELBI Study Group. Permissive hypercapnia in extremely low birth weight infants (PHELBI): a randomized controlled multicentre trial[J]. Lancet Respir Med, 2015, 3 (7): 534-543.
[29]
Cools F, Offringa M, Askie LM. Elective high frequency oscillatory ventilation versus conventional ventilation for acute pulmonary dysfunction in preterm infants[J]. Cochrane Database Syst Rev, 2015, (3): CD000104.
[30]
Wheeler K, Klingenberg C, Davis PG, et al. Volume-targeted versus pressure-limited ventilation in the neonate[J]. Cochrane Database Syst Rev, 2010, (11): CD003666.
[31]
Hermeto F, Bottino MN, Sant’Anna GM, et al. Implementation of a respiratory therapist-driven protocol for neonatal ventilation: impact on the premature population[J]. Pediatrics, 2009, 123 (5): e907-e916.
[32]
Carlo WA, Finer NN, Higgins RD, et al; Support Study group. Target ranges of oxygen saturation in extremely preterm infants[J]. N Eng J Med, 2010, 362 (21): 1959-1969.
[33]
Stenson BJ, Tarnow-Mordi WO, Brockelhurst P, et al; BOOST Ⅱ United Kingdom, Australia, and New Zealand Collaborative Groups. Oxygen saturations and outcomes in preterm infants[J]. N Eng J Med, 2013, 368 (22): 2094-2104.
[34]
Schmidt B, Whyte RK, Roberts RS, et al. Canadian Oxygen Trial (COT) group. Effects of targeting higher vs lower arterial oxygen saturations on death or disability in extremely preterm infants: a randomized clinical trial[J]. JAMA, 2013, 309 (20): 2011-2020.
[35]
Saugstad OD, Aune D. Optimal oxygenation of extremely low birth weight infants: a meta-analysis and systematic review of the oxygen saturation target studies[J]. Neonatology, 2014, 105 (1): 55-63.
[36]
Jain D, Claure N, Bancalari E, et al. Volume guarantee ventilation: effect on preterm infants with frequent hypoxemia episodes[J]. Neonatology, 2016, 110 (2): 129-134.
[37]
Claure N, D’Ugard C, Bancalari E. Automated adjustment of inspired oxygen in preterm infants with frequent fluctuations in oxygenation: a pilot clinical trial[J]. J Pediatr, 2009, 155 (5): 640-645.
[38]
Hagadorn JI, Brownell EA, Herbst KW, et al. Trends and variation in management and outcomes of very low-birth-weight infants with patent ductus arteriosus[J]. Pediatr Res, 2016, 80 (6): 785-792.
[39]
Sosenko IR, Fajardo MF, Bancalari E, et al. Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial[J]. J Pediatr, 2012, 160 (6): 929-935.
[40]
Poindexter BB, Martin CR. Impact of nutrition on bronchopulmonary dysplasia[J]. Clin Perinatol, 2015, 42 (4): 797-806.
[41]
Joss-Moore LA, Hagen-Lillevik SJ, Albertine KH, et al. Alveolar formation is dysregulated by restricted nutrition but not excessive sedation in preterm lambs managed by noninvasive support[J]. Pediatr Res, 2016, 80 (5): 719-728.
[42]
Ehrenkranz RA, Das A, William OH, et al. Early nutrition mediates the influence of severity of illness on extremely low birth weight infants[J]. Pediatr Res, 2011, 69: 522-529.
[43]
Spiegler J, Preuss M, Gopel W, et al. German Neonatal Network. Does breastmilk influence the development of bronchopulmonary dysplasia?[J]. J Pediatr, 2016, 169: 76-80.
[44]
Dicky O, Ehlinger V, Casper C; EPINUTRI Study Group. Policy of feeding very preterm infants with their mother’s own fresh milk was associated with a reduced risk of bronchopulmonary dysplasia[J]. Acta Pediatr, 2017, doi:10.1111/apa.13757.
[45]
Stephens BE, Gargus RA, Vohr BR, et al. Fluid regimens in the first week of life may increase risk of patent ductus arteriosus in extremely low birth weight infants[J]. J Perinatol, 2008, 28 (2): 123-128.
[46]
Oh W, Poindexter BB, Wright LL, et al. Association between fluid intake and weight loss during first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants[J]. J Pediatr, 2005, 147 (6): 786-790.
[47]
Schmidt B, Roberts RS, Tin W, et al; Caffeine for Apnea of Prematurity Trial Group. Caffeine therapy for apnea of prematurity[J]. N Engl J Med, 2006, 354 (20): 2112-2121.
[48]
Amaro C, Bello J, Banacalri E, et al. Caffeine to reduce length of mechanical ventilation in preterm infants. A randomized controlled trial[J]. EPAS, 2016: 2372.
[49]
Barrington KJ. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs[J]. BMC Pediatr, 2001, 1: 1.
[50]
Doyle LW, Ehrenkranz RA, Halliday HL. Early ( < 8 days) postnatal corticosteroids for chronic lung disease in preterm infants[J]. Cochrane Database Syst Rev, 2014, (5): CD001146.
[51]
Doyle LW, Ehrenkranz RA, Halliday HL. Late ( < 7 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants[J]. Cochrane Database Syst Rev, 2014, (5): CD001145.
[52]
Doyle LW, Halliday HL, Sinclair JC, et al. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease[J]. Pediatrics, 2005, 115 (3): 655-661.
[53]
Heine VM, Rowitch DH. Hedgehog signaling has a protective effect in glucocorticoid-induced mouse neonatal brain injury through an 11betaHSD2-dependent mechanism[J]. J Clin Invest, 2009, 119 (2): 267-277.
[54]
Baud O, Maury L, Alberti C, et al; PREMILOC trial study group. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants: a double-blind, placebo-controlled, multicentre, randomised trial[J]. Lancet, 2016, 387 (10030): 1827-1836.
[55]
ClinicalTrials.gov. Hydrocortisone for BPD. Clinical.Trials.gov Identifier: NCT01353313[EB/OL].[December 9, 2016]. www.clinicaltrials.gov.
[56]
BasslerD, Plavak R, Poets CF, et al; NEUROSIS Trial group. Early inhaled budesonide for the prevention of bronchopulmonary dysplasia[J]. N Eng J Med, 2015, 373 (16): 1497-1506.
[57]
Yeh TF, Chen CM, Lin HC, et al. Intratracheal administration of budesonide/surfactant to prevent bronchopulmonary dysplasia[J]. Am J Respir Crit Care Med, 2016, 193 (1): 86-95.
[58]
Bancalari E, Jain D, Jobe AH. Prevention of bronchopulmonary dysplasia: Are intratracheal steroids with surfactant a magic bullet?[J]. Am J Respir Crit Care Med, 2016, 193 (1): 12-13.
[59]
McGowan SE. Contributions of retinoids to the generation and repair of the pulmonary alveolus[J]. Chest, 2002, 121 (5 Suppl): 206S-208S.
[60]
Tyson JE, Wright LL, Fanaroff AA, et al. Vitamin A supplementation for extremely-low-birth-weight infants. National institute of child health and human development neonatal research network[J]. N Eng J Med, 1999, 340 (25): 1962-1968.
[61]
Darlow BA, Graham PJ, Rojas-Reyes MX. Vitamin A supplementation to prevent mortality and short- and long-term morbidity in very low birth weight infants[J]. Cochrane Database Syst Rev, 2016, (8): CD000501.
[62]
Couroucil XI, Placencia JL, Suresh GK, et al. Should we still use vitamin A to prevent bronchopulmonary dysplasia?[J]. J Perinatol, 2016, 36 (8): 581-585.
[63]
Meyer S, Gortner L. NeoVitA Trial Investigators. Early postnatal additional high-dose oral vitamin A supplementation versus placebo for 28 days for preventing bronchopulmonary dysplasia or death in extremely low birth weight infants[J]. Neonatology, 2014, 105 (3): 182-188.
[64]
ter Horst SA, Walther FJ, Wagennar GT, et al. Inhaled nitric oxide attenuates pulmonary inflammation and fibrin deposition and prolongs survival in neonatal hyperoxic lung injury[J]. Am J Physiol Lung Cell Mol Physiol, 2007, 293 (1): L35-L44.
[65]
BalasubramaniamV, Tang JR, Abman SH, et al. Mild hypoxia impairs alveolarization in the endothelial nitric oxide synthase-deficient mouse[J]. Am J Physiol Lung Cell Mol Physiol, 2003, 284 (6): L964-L971.
[66]
Donohue PK, Gilmore MM, Allen MC, et al. Inhaled nitric oxide in preterm infants: a systematic review[J]. Pediatrics, 2011, 127 (2): e414-e422.
McCann EM, Lewis K, Brady JP, et al. Controlled trial of furosemide therapy in infants with chronic lung disease[J]. J Pediatr, 1985, 106 (6): 957-962.
[69]
Brion LP, Primhak RA, Young W. Aerosolized diuretics for preterm infants with (or developing) chronic lung disease[J]. Cochrane Database Syst Rev, 2006, (3): CD001694.
[70]
Viscardi RM, Kallapur SG. Role of Ureaplasma respiratory tract colonization in bronchopulmonary dysplasia pathogenesis: Current concepts and update[J]. Clin Perinatol, 2015, 42 (4): 719-738.
[71]
Nair V, Loganathan P, Soraisham AS. Azithromycin and other macrolides for prevention of bronchopulmonary dysplasia: A systematic review and meta-analysis[J]. Neonatology, 2014, 106 (4): 337-347.
[72]
ClinicalTrials.gov. Trial of intravenous azithromycin to eradicate Ureaplasma respiratory tract infection in preterm infants (AZIPⅢ) [EB/OL]. [December 9, 2016]. Clinical.Trials.gov Identifier: NCT01778634. www.clinicaltrials.gov.
[73]
Levine CR, Gewolb IH, Davis JM, et al. The safety, pharmacokinetics, and anti-inflammatory effects of intratracheal recombinant human Clara cell protein in premature infants with respiratory distress syndrome[J]. Pediatr Res, 2005, 58 (1): 15-21.
[74]
ClinicalTrials.gov. Efficacy of recombinant human Clara cell protein (rhCC10) administered to premature neonates with respiratory distress syndrome[EB/OL]. [December 9, 2016]. Clinical.Trials.gov Identifier: NCT01941745. www.clinicaltrials.gov.
[75]
Sustko RP, Young KC, Suguihara C, et al. Long term reparative effects of mesenchymal stem cell therapy following neonatal hyperoxia-induced lung injury[J]. Pediatr Res, 2013, 73 (1): 46-53.
[76]
van Haaften T, Byrne R, Bonnet S, et al. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats[J]. Am J Respir Crit Care Med, 2009, 180 (11): 1131-1142.